Ingalsbe Michelle L, Wojciechowski Amy L, Smith Kelly A, Mergenhagen Kari A
Department of Pharmacy, VA Western New York Healthcare System, Buffalo, NY, USA.
Department of Pharmacy Practice, D'Youville College School of Pharmacy, Buffalo, NY, USA.
Ther Adv Urol. 2015 Aug;7(4):186-93. doi: 10.1177/1756287215581556.
The aim of the study was to assess both the safety and the effectiveness of nitrofurantoin in male veterans treated for urinary tract infections (UTIs) with varying degrees of renal impairment in the outpatient setting. Nitrofurantoin is an important oral option for treating UTIs given increasing resistance to commonly used agents. Nitrofurantoin is currently contraindicated in patients with a creatinine clearance (CrCl) of < 60 ml/min, but the reason for this threshold has not been well documented.
Data were collected through a retrospective chart review from January 2004 to July 2013 of men who had received nitrofurantoin. Bivariate analyses followed by multivariate analyses were performed between patients experiencing clinical cure and those who did not, to determine factors significantly impacting effectiveness.
The Gram stain of the organism causing the UTI and CrCl were significant factors impacting effectiveness. For every 1 ml/min increase in CrCl, the odds of clinical cure increased by 1.3%. Patients with Gram-negative UTIs predictably had 80% cure rates with CrCl around 60 ml/min. Patients with Gram-positive UTIs required higher CrCl, nearing 100 ml/min, to establish an 80% cure rate. Adverse effects did not vary with CrCl.
The odds of clinical cure varied with CrCl and with the type of organism causing the UTI, while adverse events did not differ based on renal function. A minimum CrCl of 60 ml/min is suggested for men to achieve an 80% cure rate for UTIs with the most common urinary pathogens.
本研究旨在评估在门诊环境中,呋喃妥因对不同程度肾功能损害的男性退伍军人治疗尿路感染(UTI)的安全性和有效性。鉴于常用药物的耐药性不断增加,呋喃妥因是治疗UTI的一种重要口服药物。目前,肌酐清除率(CrCl)<60 ml/min的患者禁用呋喃妥因,但这一阈值的依据尚未得到充分记录。
通过回顾性病历审查收集2004年1月至2013年7月期间接受呋喃妥因治疗的男性患者的数据。对临床治愈的患者和未治愈的患者进行双变量分析,然后进行多变量分析,以确定显著影响有效性的因素。
导致UTI的病原体的革兰氏染色和CrCl是影响有效性的重要因素。CrCl每增加1 ml/min,临床治愈的几率增加1.3%。革兰氏阴性UTI患者在CrCl约为60 ml/min时的治愈率可预测为80%。革兰氏阳性UTI患者需要更高的CrCl,接近100 ml/min,才能达到80%的治愈率。不良反应与CrCl无关。
临床治愈的几率随CrCl和导致UTI的病原体类型而变化,而不良事件与肾功能无关。建议男性患者的CrCl最低为60 ml/min,以实现对最常见尿路病原体引起的UTI的80%治愈率。